ABOUT
Revolutionizing vector engineering
by leveraging a billion years of natures wisdom.
At rAAVen, our mission is to create gene-therapy delivery vectors that enable precise, safe, and effective treatment for patients with severe and life-threatening diseases. We partner with biotech and pharmaceutical companies to translate advanced AAV capsid engineering into clinically meaningful therapies across multiple organs and indications.
Founded in 2022 in Sweden, rAAVen Therapeutics was built around a clear goal: to engineer AAV vectors with superior selectivity, efficiency, and tissue specificity compared with existing technologies. Our platform combines rational capsid design with high-throughput DNA barcoding and next-generation sequencing to identify viral variants with precisely defined properties from large libraries.
By inserting rationally designed, evolution-inspired peptides into the AAV capsid, we harness naturally optimized protein–protein interactions to enhance viral entry and targeting. Using this strategy, we have generated capsids with tailored tropism, including variants targeting oligodendrocytes, neurons, and astrocytes in the CNS, as well as vectors selectively targeting diverse kidney and pancreatic cell populations, and muscle.
Today, we collaborate with biotech and pharmaceutical partners to apply this platform across organs, tissues, and cell types, from rodent models to non-human primates and through diverse delivery routes. In parallel, we offer screening of promoter and enhancer elements to drive stronger and more selective transgene expression, supporting both improved efficacy and safety in future clinical applications.
We welcome partnerships with teams who share our ambition to push the boundaries of gene delivery—get in touch to explore how we can support your capsid engineering needs.
